Cart
×
GSK and Prosensa Will Hold a Joint Webinar on October 15
GSK and Prosensa will hold a joint webinar on 15th October at 16:00 – 17:30 GMT (17:00 – 18:30 CET, 12:00 – 13:30 EST, 09:00 – 10:30 PST). Following […]
Notes From World Muscle Society 2013
WMS 2013 was full of excitement and interest as results of current clinical trials and early stage research were discussed. Here are some highlights, thank you Abby Bronson for summarizing […]
EXON SKIPPING IN DUPLICATION 2 MOUSE PRESENTED AT WMS
Dr. Adeline Vulin from Nationwide Children’s Hospital presented the latest data from her work in Dr. Kevin Flanigan’s lab on the new duplication mouse model and the results of exon […]
PROSENSA’S PRO044 DATA PRESENTED AT WMS BY DR. NATHALIE GOEMANS
Here are top line notes from the PRO044 presentation at World Muscle Society, Oct 4. Age of inclusion: 5-16 Mean age: 9 The drug was well tolerated. They saw trace […]
Prosensa to Host Conference Call to Discuss Recent Drisapersen Data Presentations
Conference call and live webcast scheduled for 11:00 a.m. ET (5:00 p.m. CET) Tuesday, October 8, 2013 LEIDEN, The Netherlands – October 3, 2013 – Prosensa Holding N.V. (NASDAQ: RNA), […]
Sarepta Therapeutics Introduces Online Resource Center on Exon Skipping for the Duchenne Muscular Dystrophy Community
We wanted to let Duchenne families know about a new online resource on exon skipping from Sarepta Therapeutics. Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today […]
Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test Through 96 Weeks in Phase llb in Duchenne Muscular Dystrophy
We are encouraged by the promising Phase IIb data for eteplirsen, an exon-skipping compound, which we hope could be a breakthrough treatment for Duchenne muscular dystrophy. Currently, there is no […]
GSK and Prosensa announce primary endpoint not met in Phase III study of drisapersen in patients with Duchenne Muscular Dystrophy
GlaxoSmithKline (GSK) and Prosensa today announced that GSK’s Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable […]
CURE DUCHENNE DRUG DEVELOPMENT AND CLINICAL TRIAL WEBINAR SEPTEMBER 13, 2:00 PM ET
CureDuchenne has worked closely with biotech and pharmaceutical companies for the past decade with a goal of accelerating treatments for Duchenne muscular dystrophy. CureDuchenne was the first organization to partner […]